homovanillic acid has been researched along with Depression in 136 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the preset study, the authors investigated that effects of the antipsychotic drug risperidone on psychotic depression and examined the mechanism of risperidone to ameliorate psychotic depression." | 9.12 | Risperidone in the treatment of psychotic depression. ( Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2006) |
| "In 46 inpatients with severe DSM III depression, blood counts, serum and red cell folate, serum vitamin B12, total plasma homocysteine, and, in 28 patients, CSF folate, S-adenosylmethionine, and the monoamine neurotransmitter metabolites 5HIAA, HVA, and MHPG were examined." | 9.09 | Homocysteine, folate, methylation, and monoamine metabolism in depression. ( Bottiglieri, T; Carney, MW; Crellin, R; Laundy, M; Reynolds, EH; Toone, BK, 2000) |
| " In the present study, clinical characteristics, plasma level of homovanillic acid (pHVA) and two scales - the Eating Attitudes Test (EAT) and the Beck Depression Inventory (BDI) - were assessed in 36 adolescent bulimia nervosa patients (mean age16." | 7.75 | Plasma homovanillic acid in adolescents with bulimia nervosa. ( Baeza, I; Bernardo, M; Castro-Fornieles, J; Deulofeu, R; Fernández, L; Lázaro, L; Martínez-Mallen, E; Toro, J; Vila, M, 2009) |
| "Dopaminergic abnormalities have been described in anorexia nervosa but studies about plasma level of homovanillic acid (pHVA) have yielded conflicting results probably due to the small number and the heterogeneity of patients." | 7.74 | Psychopathological and nutritional correlates of plasma homovanillic acid in adolescents with anorexia nervosa. ( Baeza, I; Bernardo, M; Castro-Fornieles, J; Casulà, V; Deulofeu, R; Lázaro, L; Puig, J; Saura, B; Toro, J, 2008) |
| "In this study we investigated the cerebrospinal fluid (CSF) concentrations of 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) in Alzheimer (AD) patients (n=75), patients with mild cognitive impairment (MCI, n=9) and patients with depression (n=7)." | 7.72 | 5-Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment. ( Ganzer, S; Müller-Thomsen, T; Stuerenburg, HJ, 2004) |
| " We measured severity of depression with Beck's Depression Inventory (BDI) and Hamilton's Depression Rating Scale (HDRS), plasma concentrations of cortisol, DHEA and DHEA-S, and CSF concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), the norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) and the dopamine metabolite homovanillic acid (HVA) in 21 abstinent alcoholics after 4 weeks of abstinence and in 11 age-matched healthy control subjects." | 7.70 | Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. ( George, D; Heinz, A; Hommer, D; Linnoila, M; Weingartner, H; Wolkowitz, OM, 1999) |
| "Treatment of endogenous depression with nortriptyline (NT), at a daily dose of 150 mg, resulted in a pronounced improvement of seven of ten patients investigated." | 7.67 | Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites. ( Aberg-Wistedt, A; Bertilsson, L; Malmgren, R, 1987) |
| "In the preset study, the authors investigated that effects of the antipsychotic drug risperidone on psychotic depression and examined the mechanism of risperidone to ameliorate psychotic depression." | 5.12 | Risperidone in the treatment of psychotic depression. ( Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2006) |
| "In 46 inpatients with severe DSM III depression, blood counts, serum and red cell folate, serum vitamin B12, total plasma homocysteine, and, in 28 patients, CSF folate, S-adenosylmethionine, and the monoamine neurotransmitter metabolites 5HIAA, HVA, and MHPG were examined." | 5.09 | Homocysteine, folate, methylation, and monoamine metabolism in depression. ( Bottiglieri, T; Carney, MW; Crellin, R; Laundy, M; Reynolds, EH; Toone, BK, 2000) |
| "In a double-blind study of 24 patients with endogenous depressiona group treated with clomipramine hydrochloride (chlorimipramine) plus tryptophan was compared with a group treated with clomipramine plus placebo." | 5.04 | Potentiation of the antidepressant action of clomipramine by tryptophan. ( Bjorn-Erik, R; Carlsson, A; Nagy, A; Skott, A; Walinder, J, 1976) |
| "Our hypothesis is that varenicline decreases the plasma levels of catecholamine metabolites; such a decrease is associated with the main mechanisms of smoking cessation and leads to a depressive state." | 3.78 | Plasma levels of metabolites of catecholamine in nicotine-dependent patients treated with varenicline. ( Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Umene-Nakano, W; Yoshii, C; Yoshimura, R, 2012) |
| " In the present study, clinical characteristics, plasma level of homovanillic acid (pHVA) and two scales - the Eating Attitudes Test (EAT) and the Beck Depression Inventory (BDI) - were assessed in 36 adolescent bulimia nervosa patients (mean age16." | 3.75 | Plasma homovanillic acid in adolescents with bulimia nervosa. ( Baeza, I; Bernardo, M; Castro-Fornieles, J; Deulofeu, R; Fernández, L; Lázaro, L; Martínez-Mallen, E; Toro, J; Vila, M, 2009) |
| "Dopaminergic abnormalities have been described in anorexia nervosa but studies about plasma level of homovanillic acid (pHVA) have yielded conflicting results probably due to the small number and the heterogeneity of patients." | 3.74 | Psychopathological and nutritional correlates of plasma homovanillic acid in adolescents with anorexia nervosa. ( Baeza, I; Bernardo, M; Castro-Fornieles, J; Casulà, V; Deulofeu, R; Lázaro, L; Puig, J; Saura, B; Toro, J, 2008) |
| "In this study we investigated the cerebrospinal fluid (CSF) concentrations of 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) in Alzheimer (AD) patients (n=75), patients with mild cognitive impairment (MCI, n=9) and patients with depression (n=7)." | 3.72 | 5-Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment. ( Ganzer, S; Müller-Thomsen, T; Stuerenburg, HJ, 2004) |
| " We measured severity of depression with Beck's Depression Inventory (BDI) and Hamilton's Depression Rating Scale (HDRS), plasma concentrations of cortisol, DHEA and DHEA-S, and CSF concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), the norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) and the dopamine metabolite homovanillic acid (HVA) in 21 abstinent alcoholics after 4 weeks of abstinence and in 11 age-matched healthy control subjects." | 3.70 | Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations. ( George, D; Heinz, A; Hommer, D; Linnoila, M; Weingartner, H; Wolkowitz, OM, 1999) |
| "We have measured the concentrations of dopamine, and the dopamine metabolites homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC), in five brain regions from suicide victims with a firm retrospective diagnosis of depression, and matched controls." | 3.69 | Reduced dopamine turnover in the basal ganglia of depressed suicides. ( Bowden, C; Cheetham, SC; Crompton, MR; Horton, RW; Katona, CL; Lowther, S, 1997) |
| "We have investigated the possible associations between the demographic, clinical and psychological characteristics of 80 patients with low back pain and the CSF levels of 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG), the principal central nervous system metabolites of serotonin, dopamine and noradrenaline, and of tryptophan, the amino acid precursor of serotonin." | 3.67 | Neurotransmission and the experience of low back pain; no association between CSF monoamine metabolites and pain. ( Alaranta, H; Hurme, M; Hyyppä, MT; Lahtela, K; Scheinin, H; Scheinin, M, 1985) |
| "Treatment of endogenous depression with nortriptyline (NT), at a daily dose of 150 mg, resulted in a pronounced improvement of seven of ten patients investigated." | 3.67 | Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites. ( Aberg-Wistedt, A; Bertilsson, L; Malmgren, R, 1987) |
| "5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were measured in the lumbar cerebrospinal fluid of 57 drug-free female patients with DSM-III diagnoses of major unipolar or bipolar depression (n = 14), schizophrenic disorder (n = 18), alcohol dependence (n = 13) and a group of other disorders (n = 12)." | 3.66 | Amine metabolites and neuroendocrine responses related to depression and suicide. ( Arató, M; Banki, CM, 1983) |
| "The authors report cerebrospinal fluid (CSF) concentrations of five monoamine metabolites before and after probenecid administration in normal subjects and patients with depression and schizophrenia." | 3.66 | CSF monoamine metabolites in depression and schizophrenia. ( Anderson, PJ; Barchas, JD; Berger, PA; Davis, KL; Faull, KF; Kilkowski, J; Kraemer, H, 1980) |
| "The probenecid technique was used in study of the central dopamine DA metabolism in patients with depressions, psychotic disorders, and Parkinson's disease." | 3.65 | Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. ( Korf, J; Praag, HM; Schut, T, 1975) |
| " The ratio of blood tyrosine and tryptophan is disturbed during depression and recovers during remission." | 3.65 | Biochemical post-mortem findings in depressed patients. ( Birkmayer, W; Riederer, P, 1975) |
| "Depression is one of the leading causes of disability in developing countries including Pakistan." | 1.46 | Depressive symptoms, monoamines levels, MAO-B activity and effect of treatment in a subset of depressed individuals from government sector hospital at Karachi. ( Farooq, AD; Naqvi, S; Rahman, R; Zeb, F, 2017) |
| "Depression and aggression in Alzheimer's disease (AD) are 2 of the most severe and prominent neuropsychiatric symptoms (NPS)." | 1.40 | Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. ( Aerts, T; De Deyn, PP; Engelborghs, S; Van Dam, D; Vermeiren, Y, 2014) |
| " Taken together, our data indicate that chronic use of stanozolol significantly affects brain monoamines leading to neurochemical modifications possibly involved in depression and stress-related states." | 1.38 | Neurochemical consequence of steroid abuse: stanozolol-induced monoaminergic changes. ( Colaianna, M; Cuomo, V; Morgese, MG; Schiavone, S; Trabace, L; Tucci, P; Zotti, M, 2012) |
| " In 46 children from this sample it was dosed plasmatic cortisol and the urinary excretion of catecholamine, VMA, HVA and 5-HIAA." | 1.28 | Biochemical correlate of depression in children. ( Basques, JC; Fabre, ZL; Fernandes, ML; Furtado, CR; Lippi, JR; Lombardi, AB; Peixoto, CC; Queiroz, EA; Soares, TA, 1991) |
| "Patients with Parkinson's disease have a decrement in homovanillic acid that is reversed by treatment with L-3,4-dihydroxyphenylalanine." | 1.27 | Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. ( Aguado, EG; de Yebenes, JG; Mena, MA, 1984) |
| "Depression is a common symptom in patients with Parkinson's disease." | 1.27 | Altered serotonin metabolism in depressed patients with parkinson's disease. ( Cote, L; Mayeux, R; Stern, Y; Williams, JB, 1984) |
| "50 pmol/ml) did not change after 1 wk of Li dosing (1." | 1.27 | Differences in lithium effects in depressed and healthy subjects. ( Karoum, F; Linnoila, M; Potter, WZ; Ross, RJ; Rudorfer, MV, 1985) |
| "Depression was by far the most important factor." | 1.26 | Cortisol in the CSF of depressed and suicidal patients. ( Asberg, M; Bertilsson, L; Lantto, O; Schalling, D; Träskman, L; Tybring, G, 1980) |
| "Nortriptyline is a preferential noradrenaline uptake inhibitor, while the dimethylated compound, chlorimipramine also has a profound influence on serotonin neurons." | 1.26 | Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects. ( Asberg, M, 1976) |
| "Lethargy and mental depression are early symptoms, followed by mild parkinsonism and progressive weight loss." | 1.26 | Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. ( Ahmad, D; Barnett, HJ; Bratty, P; Hahn, A; Lloyd, KG; McGeer, EG; Perry, TL; Purdy, A, 1979) |
| "Two cases of depression are presented: One which responded to psychotherapy and the other which responded to medication." | 1.26 | Repertory grid and biochemical characterization of depression: a comparison of case reports. ( Berger, PA; Slater, P; Yesavage, JA, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 86 (63.24) | 18.7374 |
| 1990's | 10 (7.35) | 18.2507 |
| 2000's | 20 (14.71) | 29.6817 |
| 2010's | 15 (11.03) | 24.3611 |
| 2020's | 5 (3.68) | 2.80 |
| Authors | Studies |
|---|---|
| Ikenouchi, A | 1 |
| Okamoto, N | 1 |
| Igata, R | 1 |
| Natsuyama, T | 1 |
| Yoshimura, R | 4 |
| Tian, P | 1 |
| Zhang, W | 1 |
| Li, KY | 1 |
| Li, HW | 1 |
| Ma, K | 1 |
| Han, DE | 1 |
| Saloner, R | 1 |
| Cherner, M | 1 |
| Grelotti, DJ | 1 |
| Paolillo, EW | 1 |
| Moore, DJ | 1 |
| Heaton, RK | 1 |
| Letendre, SL | 1 |
| Kumar, A | 1 |
| Grant, I | 1 |
| Ellis, RJ | 1 |
| Chojnacki, C | 1 |
| Poplawski, T | 1 |
| Blasiak, J | 1 |
| Fila, M | 1 |
| Konrad, P | 1 |
| Chojnacki, J | 1 |
| Monchaux De Oliveira, C | 1 |
| Pourtau, L | 1 |
| Vancassel, S | 1 |
| Pouchieu, C | 1 |
| Capuron, L | 1 |
| Gaudout, D | 1 |
| Castanon, N | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Romańska, I | 1 |
| Wąsik, A | 1 |
| Michaluk, J | 1 |
| Khnychenko, LK | 1 |
| Yakovleva, EE | 1 |
| Bychkov, ER | 1 |
| Shabanov, PD | 1 |
| Gaum, PM | 1 |
| Gube, M | 1 |
| Schettgen, T | 1 |
| Putschögl, FM | 1 |
| Kraus, T | 1 |
| Fimm, B | 1 |
| Lang, J | 1 |
| Zeb, F | 1 |
| Naqvi, S | 1 |
| Rahman, R | 1 |
| Farooq, AD | 1 |
| Ogawa, S | 1 |
| Kunugi, H | 1 |
| Knorr, U | 1 |
| Forman, J | 1 |
| Pech, J | 1 |
| Kessing, LV | 1 |
| Luykx, JJ | 1 |
| Bakker, SC | 1 |
| van Geloven, N | 1 |
| Eijkemans, MJ | 1 |
| Horvath, S | 1 |
| Lentjes, E | 1 |
| Boks, MP | 1 |
| Strengman, E | 1 |
| DeYoung, J | 1 |
| Buizer-Voskamp, JE | 1 |
| Cantor, RM | 1 |
| Lu, A | 1 |
| van Dongen, EP | 1 |
| Borgdorff, P | 1 |
| Bruins, P | 1 |
| Kahn, RS | 1 |
| Ophoff, RA | 1 |
| Kutsuzawa, Y | 1 |
| Kunii, Y | 1 |
| Miura, I | 1 |
| Kanno-Nozaki, K | 1 |
| Mashiko, H | 1 |
| Yabe, H | 1 |
| Niwa, S | 1 |
| Vermeiren, Y | 1 |
| Van Dam, D | 1 |
| Aerts, T | 1 |
| Engelborghs, S | 1 |
| De Deyn, PP | 1 |
| Loseva, EV | 1 |
| Sarkisova, KY | 1 |
| Loginova, NA | 1 |
| Kudrin, VS | 1 |
| Hama, S | 1 |
| Murakami, T | 1 |
| Yamashita, H | 1 |
| Onoda, K | 1 |
| Yamawaki, S | 1 |
| Kurisu, K | 1 |
| Miller, AH | 2 |
| Lindqvist, D | 1 |
| Janelidze, S | 1 |
| Hagell, P | 1 |
| Erhardt, S | 1 |
| Samuelsson, M | 1 |
| Minthon, L | 1 |
| Hansson, O | 1 |
| Björkqvist, M | 1 |
| Träskman-Bendz, L | 1 |
| Brundin, L | 1 |
| Castro-Fornieles, J | 2 |
| Deulofeu, R | 2 |
| Martínez-Mallen, E | 1 |
| Baeza, I | 2 |
| Fernández, L | 1 |
| Lázaro, L | 2 |
| Toro, J | 2 |
| Vila, M | 1 |
| Bernardo, M | 2 |
| Brambilla, F | 1 |
| Dalle Grave, R | 1 |
| Calugi, S | 1 |
| Marchesini, G | 1 |
| Baroni, S | 1 |
| Marazziti, D | 1 |
| Nakano, W | 1 |
| Nakamura, K | 1 |
| Shi, X | 1 |
| Zhang, L | 1 |
| Fu, S | 1 |
| Li, N | 1 |
| Umene-Nakano, W | 1 |
| Yoshii, C | 1 |
| Hayashi, K | 1 |
| Ikenouchi-Sugita, A | 1 |
| Katsuki, A | 1 |
| Hori, H | 1 |
| Nakamura, J | 2 |
| Tucci, P | 1 |
| Morgese, MG | 1 |
| Colaianna, M | 1 |
| Zotti, M | 1 |
| Schiavone, S | 1 |
| Cuomo, V | 1 |
| Trabace, L | 1 |
| Miura, H | 2 |
| Qiao, H | 2 |
| Ohta, T | 2 |
| Dalla, C | 1 |
| Antoniou, K | 1 |
| Papadopoulou-Daifoti, Z | 1 |
| Balthazart, J | 1 |
| Bakker, J | 1 |
| Carpenter, LL | 1 |
| Moreno, FA | 1 |
| Kling, MA | 1 |
| Anderson, GM | 1 |
| Regenold, WT | 1 |
| Labiner, DM | 1 |
| Price, LH | 1 |
| Stuerenburg, HJ | 1 |
| Ganzer, S | 1 |
| Müller-Thomsen, T | 1 |
| Mitani, H | 1 |
| Shirayama, Y | 1 |
| Yamada, T | 1 |
| Kawahara, R | 1 |
| Goto, M | 1 |
| Kakihara, S | 1 |
| Shinkai, K | 1 |
| Yamada, Y | 1 |
| Kaji, K | 1 |
| Ueda, N | 1 |
| Sher, L | 1 |
| Oquendo, MA | 1 |
| Grunebaum, MF | 1 |
| Burke, AK | 1 |
| Huang, YY | 1 |
| Mann, JJ | 1 |
| Casulà, V | 1 |
| Saura, B | 1 |
| Puig, J | 1 |
| Dávila, R | 1 |
| Zumárraga, M | 1 |
| Basterreche, N | 1 |
| Arrúe, A | 1 |
| Anguiano, JB | 1 |
| Dhir, A | 1 |
| Kulkarni, SK | 1 |
| Felger, JC | 1 |
| Alagbe, O | 1 |
| Hu, F | 1 |
| Mook, D | 1 |
| Freeman, AA | 1 |
| Sanchez, MM | 1 |
| Kalin, NH | 1 |
| Ratti, E | 1 |
| Nemeroff, CB | 1 |
| Mayeux, R | 2 |
| Träskman, L | 3 |
| Tybring, G | 2 |
| Asberg, M | 5 |
| Bertilsson, L | 3 |
| Lantto, O | 1 |
| Schalling, D | 1 |
| Curzon, G | 2 |
| Kantamaneni, BD | 2 |
| Van Boxel, P | 1 |
| Gillman, PK | 1 |
| Bartlett, JR | 2 |
| Bridges, PK | 2 |
| Anokhina, IP | 1 |
| Gamaleia, NB | 1 |
| Oreland, L | 1 |
| Wiberg, A | 1 |
| Sjöstrand, L | 1 |
| Thorén, P | 2 |
| Krzyzowski, J | 1 |
| Lewicka-Wysocka, H | 1 |
| Lukaszewska, B | 1 |
| Marcjan, K | 1 |
| Pacyna, M | 1 |
| Pietruszewska, I | 1 |
| Roguska, E | 1 |
| Stencka, K | 1 |
| Misionzhnik, EIu | 2 |
| Vertogradova, OP | 1 |
| Krasnov, VN | 1 |
| Salenko, BB | 1 |
| Klok, CJ | 1 |
| Brouwer, GJ | 1 |
| van Praag, HM | 6 |
| Doogan, D | 1 |
| Hallert, C | 1 |
| Aström, J | 1 |
| Sedvall, G | 1 |
| Banki, CM | 2 |
| Arató, M | 1 |
| Stern, Y | 1 |
| Cote, L | 1 |
| Williams, JB | 1 |
| Mena, MA | 1 |
| Aguado, EG | 1 |
| de Yebenes, JG | 1 |
| Berger, PA | 3 |
| Faull, KF | 1 |
| Kilkowski, J | 1 |
| Anderson, PJ | 1 |
| Kraemer, H | 2 |
| Davis, KL | 1 |
| Barchas, JD | 2 |
| Rossetti, ZL | 1 |
| Lai, M | 1 |
| Hmaidan, Y | 1 |
| Gessa, GL | 1 |
| Suzuki, E | 1 |
| Kanba, S | 1 |
| Koshikawa, H | 1 |
| Nibuya, M | 1 |
| Yagi, G | 1 |
| Asai, M | 1 |
| Hibbeln, JR | 1 |
| Umhau, JC | 1 |
| George, DT | 1 |
| Salem, N | 1 |
| Bowden, C | 1 |
| Cheetham, SC | 1 |
| Lowther, S | 1 |
| Katona, CL | 1 |
| Crompton, MR | 1 |
| Horton, RW | 1 |
| Rilke, O | 1 |
| Safar, C | 1 |
| Israel, M | 1 |
| Barth, T | 1 |
| Felber, W | 1 |
| Oehler, J | 1 |
| Sallinen, J | 1 |
| Haapalinna, A | 1 |
| MacDonald, E | 1 |
| Viitamaa, T | 1 |
| Lähdesmäki, J | 1 |
| Rybnikova, E | 1 |
| Pelto-Huikko, M | 1 |
| Kobilka, BK | 1 |
| Scheinin, M | 2 |
| Galinowski, A | 1 |
| Heinz, A | 1 |
| Weingartner, H | 1 |
| George, D | 1 |
| Hommer, D | 1 |
| Wolkowitz, OM | 1 |
| Linnoila, M | 2 |
| Bottiglieri, T | 1 |
| Laundy, M | 1 |
| Crellin, R | 1 |
| Toone, BK | 1 |
| Carney, MW | 1 |
| Reynolds, EH | 1 |
| Yadid, G | 1 |
| Overstreet, DH | 1 |
| Zangen, A | 1 |
| Ventura, R | 1 |
| Cabib, S | 1 |
| Puglisi-Allegra, S | 1 |
| Pallis, E | 1 |
| Thermos, K | 1 |
| Spyraki, C | 1 |
| Jimerson, DC | 3 |
| Post, RM | 12 |
| Skyler, J | 1 |
| Bunney, WE | 5 |
| Ringberger, VA | 1 |
| Sjöqvist, F | 1 |
| Tuck, JR | 1 |
| Purdy, A | 1 |
| Hahn, A | 1 |
| Barnett, HJ | 1 |
| Bratty, P | 1 |
| Ahmad, D | 1 |
| Lloyd, KG | 1 |
| McGeer, EG | 1 |
| Perry, TL | 1 |
| Sweeney, D | 1 |
| Nelson, C | 1 |
| Bowers, M | 1 |
| Maas, J | 1 |
| Heninger, G | 2 |
| Roccatagliata, G | 1 |
| Albano, C | 1 |
| Cocito, L | 1 |
| Maffini, M | 1 |
| Puca, FM | 3 |
| Livrea, P | 3 |
| Genco, S | 3 |
| Specchio, LM | 3 |
| Bandiera, L | 2 |
| DiReda, L | 1 |
| Gerner, RH | 3 |
| Carman, JS | 1 |
| Gillin, JC | 2 |
| Goodwin, FK | 12 |
| Bowers, MB | 6 |
| Moore, D | 1 |
| Tarsy, D | 1 |
| Study, RE | 1 |
| Maas, JW | 1 |
| Riederer, P | 3 |
| Tenk, H | 1 |
| Werner, H | 1 |
| Bischko, J | 1 |
| Rett, A | 1 |
| Krisper, H | 1 |
| Praag, HM | 2 |
| Meltzer, HY | 1 |
| Young, M | 1 |
| Metz, J | 1 |
| Fang, VS | 1 |
| Schyve, PM | 1 |
| Arora, RC | 1 |
| Zarcone, VP | 1 |
| Brodie, KH | 1 |
| Sack, R | 2 |
| Van Scheyen, JD | 1 |
| Korf, J | 4 |
| Sandler, M | 1 |
| Ruthven, CR | 1 |
| Goodwin, BL | 1 |
| Reynolds, GP | 1 |
| Rao, VA | 1 |
| Coppen, A | 2 |
| Gold, PW | 1 |
| Wehr, T | 1 |
| Rebar, R | 1 |
| Terenius, L | 1 |
| Wahlström, A | 1 |
| Agren, H | 1 |
| Yesavage, JA | 1 |
| Slater, P | 1 |
| Heninger, GR | 1 |
| Vestergaard, P | 1 |
| Sørensen, T | 1 |
| Hoppe, E | 1 |
| Rafaelsen, OJ | 1 |
| Yates, CM | 1 |
| Nicolaou, N | 1 |
| Major, LJ | 1 |
| Murphy, DL | 1 |
| Lipper, S | 1 |
| Gordon, E | 1 |
| Kirstein, L | 1 |
| Schilkrut, R | 1 |
| Rüther, E | 1 |
| Ackenheil, M | 1 |
| Eben, E | 1 |
| Hippius, H | 1 |
| Walinder, J | 1 |
| Skott, A | 1 |
| Carlsson, A | 1 |
| Nagy, A | 1 |
| Bjorn-Erik, R | 1 |
| Sepping, P | 1 |
| Di Reda, L | 2 |
| Lamberti, P | 1 |
| Papagno, G | 1 |
| Takahashi, S | 2 |
| Kondo, H | 2 |
| Kato, N | 2 |
| Ban, TA | 1 |
| Jori, A | 1 |
| Dolfini, E | 1 |
| Casati, C | 1 |
| Argenta, G | 1 |
| Siever, L | 1 |
| Angwin, P | 1 |
| Berger, P | 1 |
| Zarcone, V | 1 |
| Barchas, J | 1 |
| Brodie, HK | 1 |
| Schut, T | 1 |
| Gordon, EK | 1 |
| Birkmayer, W | 2 |
| Gaillard, JM | 1 |
| Constantinidis, J | 1 |
| Tissot, R | 1 |
| Abrams, R | 1 |
| Essman, WB | 1 |
| Taylor, MA | 1 |
| Fink, M | 1 |
| Kotin, J | 1 |
| Zubenko, GS | 1 |
| Moossy, J | 1 |
| Kopp, U | 1 |
| Queiroz, EA | 1 |
| Lombardi, AB | 1 |
| Furtado, CR | 1 |
| Peixoto, CC | 1 |
| Soares, TA | 1 |
| Fabre, ZL | 1 |
| Basques, JC | 1 |
| Fernandes, ML | 1 |
| Lippi, JR | 1 |
| Wägner, A | 1 |
| Malmgren, R | 1 |
| Aberg-Wistedt, A | 1 |
| Przuntek, H | 1 |
| Kuhn, W | 1 |
| Kraus, P | 1 |
| Rudorfer, MV | 1 |
| Karoum, F | 1 |
| Ross, RJ | 1 |
| Potter, WZ | 1 |
| Hyyppä, MT | 1 |
| Scheinin, H | 1 |
| Alaranta, H | 1 |
| Hurme, M | 1 |
| Lahtela, K | 1 |
| Metcalfe, M | 1 |
| Carroll, JD | 1 |
| Morris, JG | 1 |
| Ashcroft, GW | 1 |
| Blackburn, IM | 1 |
| Eccleston, D | 1 |
| Glen, AI | 1 |
| Hartley, W | 1 |
| Kinloch, NE | 1 |
| Lonergan, M | 1 |
| Murray, LG | 1 |
| Pullar, IA | 1 |
| Schildkraut, JJ | 2 |
| Weiss, BL | 1 |
| Kupfer, DJ | 1 |
| Foster, FG | 1 |
| Delgado, J | 1 |
| Yamane, H | 1 |
| Tani, N | 1 |
| Angrist, B | 1 |
| Sathananthan, G | 1 |
| Wilk, S | 1 |
| Gershon, S | 1 |
| McClure, DJ | 1 |
| Sack, RL | 2 |
| Neumayer, E | 1 |
| Ambrozi, L | 1 |
| Linauer, W | 1 |
| Iurkin, MM | 1 |
| Polishchuk, IuI | 1 |
| Granerus, AK | 1 |
| Magnusson, T | 1 |
| Roos, BE | 1 |
| Svanborg, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Kynurenine Pathway Metabolites in Perinatal Depression and Suicidality[NCT02566980] | 209 participants (Actual) | Observational | 2014-10-23 | Completed | |||
| Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794] | 61 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Study by 1H NMR of the Variations of the Metabolome During the Course of Electroconvulsive Therapy in Patients With Major Depressive Episode[NCT05973643] | 50 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6
| Intervention | incidents of an adverse event (Number) |
|---|---|
| Double rTMS | 18 |
| M1 Active rTMS + DLPFC Sham rTMS | 14 |
| DLPFC Active rTMS + M1 Sham rTMS | 1 |
| Double Sham rTMS | 1 |
To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 18.7 | 18.1 | 19.0 | 19.3 | 15.8 |
| Double rTMS | 15.6 | 16.2 | 17 | 16.9 | 17.8 |
| Double Sham rTMS | 16.3 | 15.5 | 15.0 | 16.1 | 16.2 |
| M1 Active rTMS + DLPFC Sham rTMS | 15.9 | 16.9 | 14.6 | 15.1 | 12.4 |
To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.7 | 18.2 | 20.2 | 19.0 | 15.7 |
| Double rTMS | 23.2 | 20.7 | 16.4 | 17.9 | 20.1 |
| Double Sham rTMS | 18.8 | 13.7 | 13.1 | 14.7 | 16.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 18.5 | 16.5 | 16.7 | 19.1 | 16.3 |
To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 33.4 | 27.6 | 30.8 | 31.4 | 24.8 |
| Double rTMS | 36.3 | 34.2 | 31.7 | 33.1 | 33.4 |
| Double Sham rTMS | 37.5 | 32.4 | 28.2 | 28.5 | 35.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 34.3 | 31.0 | 30.8 | 27.3 | 28.1 |
To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-Treatment): Severity | Week 1 Post Treatment: Severity | Week 1 Post Treatment: Improvement | Month 1 Post Treatment: Severity | Month 1 Post Treatment: Improvement | Month 3 Post Treatment: Severity | Month 3 Post Treatment: Improvement | Month 6 Post Treatment: Severity | Month 6 Post Treatment: Improvement | |
| DLPFC Active rTMS + M1 Sham rTMS | 4.3 | 4.7 | 3.5 | 4.4 | 3.7 | 4.4 | 3.6 | 4.3 | 3.7 |
| Double rTMS | 4.9 | 4.8 | 3.6 | 4.4 | 3.5 | 4.6 | 3.7 | 4.2 | 3.5 |
| Double Sham rTMS | 3.6 | 3.9 | 3.0 | 4.1 | 3.5 | 4.4 | 3.6 | 4.6 | 3.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 4.7 | 4.9 | 3.5 | 4.8 | 3.8 | 3.8 | 3.4 | 5.0 | 4.2 |
"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 13.8 | 9.4 | 12.4 | 10.4 | 10.4 |
| Double rTMS | 15.2 | 11.3 | 10.6 | 10.7 | 10.4 |
| Double Sham rTMS | 14.1 | 9.3 | 8.0 | 11.1 | 10.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 16.7 | 11.2 | 10.1 | 10.1 | 8.6 |
To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 27.3 | 26.3 | 26.8 | 26.7 | 26.6 |
| Double rTMS | 28.2 | 26.8 | 28.8 | 26.5 | 28.0 |
| Double Sham rTMS | 26.2 | 27.8 | 28.7 | 24.9 | 28.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.6 | 27.1 | 27.2 | 25.3 | 27.9 |
"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 32.8 | 30.3 | 29.3 | 31.5 | 28.8 |
| Double rTMS | 32.3 | 31.2 | 30.1 | 29.6 | 30.5 |
| Double Sham rTMS | 28.9 | 28.2 | 28.6 | 28.6 | 29.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 33.1 | 27.4 | 28.1 | 33.2 | 30.6 |
To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 51.9 | 46.8 | 49.4 | 49.4 | 49 |
| Double rTMS | 57.6 | 51.2 | 49.9 | 51.7 | 50.5 |
| Double Sham rTMS | 55.5 | 43.1 | 40.9 | 43.1 | 47.5 |
| M1 Active rTMS + DLPFC Sham rTMS | 61.5 | 60.7 | 56.8 | 53.1 | 48.3 |
"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.5 | 19.3 | 19.9 | 18.9 | 20.2 |
| Double rTMS | 25.4 | 23.3 | 21.8 | 21.1 | 23.8 |
| Double Sham rTMS | 19.6 | 15.5 | 16.5 | 16.9 | 18.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.1 | 23.2 | 23.0 | 23.2 | 22.7 |
11 reviews available for homovanillic acid and Depression
| Article | Year |
|---|---|
Behavioral manifestations of movement disorders. Parkinson's and Huntington's disease.
Topics: Adult; Aged; Dementia; Depression; Depressive Disorder; Homovanillic Acid; Humans; Huntington Diseas | 1984 |
Do plasma polyunsaturates predict hostility and depression?
Topics: Adult; Cholesterol; Depression; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Female; Homovanillic | 1997 |
Studies of amine metabolites in affective illness and in schizophrenia: a comparative analysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Antidepressive Agents, Tricyclic; Bipolar Disorder; Brain; Depressio | 1975 |
Therapy-resistant depressions: biochemical and pharmacological considerations.
Topics: Adjustment Disorders; Antidepressive Agents; Brain; Depression; Drug Resistance; Homovanillic Acid; | 1975 |
Pharmacotherapy of depression--a critical review.
Topics: Adjustment Disorders; Antidepressive Agents, Tricyclic; Bipolar Disorder; Brain; Depression; Dopamin | 1975 |
Biochemical effects of antidepressant treatment--studies of monoamine metabolites in cerebrospinal fluid and platelet [3H]imipramine binding.
Topics: Antidepressive Agents; Blood Platelets; Depression; Homovanillic Acid; Humans; Hydroxyindoleacetic A | 1986 |
Simulated behavior states: an approach to specificity in psychobiological research.
Topics: Biology; Bipolar Disorder; Cyclic AMP; Depression; Emotions; Homovanillic Acid; Humans; Hydroxyindol | 1973 |
Biogenic amines and affective disorders.
Topics: Affective Symptoms; Biogenic Amines; Bipolar Disorder; Blood Platelets; Brain; Catechol O-Methyltran | 1974 |
The current status of biological criteria for classifying the depressive disorders and predicting responses to treatment.
Topics: Adult; Aged; Catechol O-Methyltransferase; Depression; Dextroamphetamine; Dihydroxyphenylalanine; Do | 1974 |
The role of dopamine in depression.
Topics: Animals; Brain; Brain Chemistry; Depression; Dopamine; Homovanillic Acid; Humans; Locomotion; Norepi | 1973 |
Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover.
Topics: Adult; Affective Symptoms; Anger; Bipolar Disorder; Central Nervous System; Depression; Diagnosis, D | 1974 |
18 trials available for homovanillic acid and Depression
| Article | Year |
|---|---|
Altered dopamine signalling in chronic epigastric pain syndrome.
Topics: Abdominal Pain; Adult; Benzamides; Benzyl Compounds; Case-Control Studies; Chronic Pain; Depression; | 2020 |
Effects of cognitive-behavioral therapy on Eating Disorders: neurotransmitter secretory response to treatment.
Topics: Adult; Anxiety; Biogenic Monoamines; Body Mass Index; Cognitive Behavioral Therapy; Depression; Feed | 2010 |
Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Biogenic Monoamines; Case-Control Studies; Chrom | 2004 |
Risperidone in the treatment of psychotic depression.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Depression; Dose-Res | 2006 |
Fluvoxamine and clomipramine in depressed patients. A double-blind clinical study.
Topics: Adult; Aged; Antidepressive Agents; Clinical Trials as Topic; Clomipramine; Depression; Diazepam; Do | 1981 |
Homocysteine, folate, methylation, and monoamine metabolism in depression.
Topics: Adult; Biogenic Monoamines; Blood Cell Count; Body Weight; Depression; Erythrocytes; Female; Folic A | 2000 |
Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response.
Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Depression; Double-Blind Method; Female; Homovani | 1978 |
Tardive dyskinesia: a clinical test of the supersensitivity hypothesis.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclic AMP; Depression; Dyskinesia, Drug-Induced; Female; Hom | 1979 |
The indoleamine hypothesis of depression: an overview and pilot study.
Topics: 5-Hydroxytryptophan; Adult; Aged; Carbidopa; Clinical Trials as Topic; Depression; Female; Homovanil | 1977 |
Controlled study comparing nomifensine and clomipramine in unipolar depression, using the probenecid technique.
Topics: Adult; Clinical Trials as Topic; Clomipramine; Depression; Dibenzazepines; Double-Blind Method; Fema | 1977 |
Potentiation of the antidepressant action of clomipramine by tryptophan.
Topics: Adolescent; Adult; Aged; Anxiety; Clomipramine; Depression; Dibenzazepines; Drug Synergism; Drug The | 1976 |
Effect of ECT and imipramine treatment on the concentration of 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) in the cerebrospinal fluid of depressed patients.
Topics: Adult; Clinical Trials as Topic; Depression; Electroconvulsive Therapy; Female; Homovanillic Acid; H | 1975 |
Levodopa and L-tryptophan therapy in Parkinsonism.
Topics: Aged; Depression; Dihydroxyphenylalanine; Female; Gait; Homovanillic Acid; Humans; Hydroxyindoleacet | 1972 |
Estimation of brain amine metabolism in affective illness: cerebrospinal fluid studies utilizing probenecid.
Topics: Bipolar Disorder; Brain; Depression; Dihydroxyphenylalanine; Fenclonine; Homovanillic Acid; Humans; | 1974 |
Amitriptyline in man: decreased formation of central 5-hydroxyindoleacetic acid.
Topics: Aged; Amitriptyline; Clinical Trials as Topic; Depression; Female; Homovanillic Acid; Humans; Hydrox | 1974 |
Serotonin metabolism in depression: clinical application of the probenecid test.
Topics: 5-Hydroxytryptophan; Adjustment Disorders; Administration, Oral; Clinical Trials as Topic; Depressio | 1974 |
Behavioral effects of a new dopamine-beta-hydroxylase inhibitor (fusaric acid) in man.
Topics: Administration, Oral; Bipolar Disorder; Clinical Trials as Topic; Depression; Dopamine beta-Hydroxyl | 1974 |
Effects of amitriptyline and imipramine on amine metabolites in the cerebrospinal fluid of depressed patients.
Topics: Adult; Amitriptyline; Biological Transport; Brain Chemistry; Depression; Dopamine; Female; Homovanil | 1974 |
107 other studies available for homovanillic acid and Depression
| Article | Year |
|---|---|
The Molecular Mechanism of Exercise for Treatment of Patients with Major Depression: A Preliminary Report on the Dynamics of Metabolites of Nitric Oxide and Catecholamines.
Topics: Catecholamines; Depression; Depressive Disorder, Major; Homovanillic Acid; Humans; Methoxyhydroxyphe | 2022 |
[Effect of Rehmanniae Radix on depression-like behavior and hippocampal monoamine neurotransmitters of chronic unpredictable mild stress model rats].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Chromatography, Liquid; Depression; | 2022 |
Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease.
Topics: Adult; Biomarkers; Depression; Dopamine; HIV Infections; Homovanillic Acid; Humans | 2020 |
Saffron Extract-Induced Improvement of Depressive-Like Behavior in Mice Is Associated with Modulation of Monoaminergic Neurotransmission.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Antidepressive Agents; Anxiety; Behav | 2021 |
Antidepressant-Like Effect of the Endogenous Neuroprotective Amine, 1MeTIQ in Clonidine-Induced Depression: Behavioral and Neurochemical Studies in Rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Biogenic Monoamines; Brain; Brain Che | 2017 |
Effects of Fluorencarbonic Acid Derivative on the Levels of Monoamines and Their Metabolites in Brain Structures of Rats with Modeled Depression-Like State.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Brain; Chromatography, High Pressure L | 2017 |
Polychlorinated biphenyls and depression: cross-sectional and longitudinal investigation of a dopamine-related Neurochemical path in the German HELPcB surveillance program.
Topics: Adult; Body Burden; Cross-Sectional Studies; Depression; Dopamine; Environmental Exposure; Environme | 2017 |
Depressive symptoms, monoamines levels, MAO-B activity and effect of treatment in a subset of depressed individuals from government sector hospital at Karachi.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents, Second-Generation; Biomarkers; Case-Control | 2017 |
Evidence for reduced homovanillic acid (HVA) in the cerebrospinal fluid of patients with depression.
Topics: Depression; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Neurotransmitt | 2019 |
Low level of evidence for reduced homovanillic acid (HVA) in the cerebrospinal fluid of patients with depression compared to healthy non-psychiatric control individuals.
Topics: Depression; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Neurotransmitt | 2019 |
Seasonal variation of serotonin turnover in human cerebrospinal fluid, depressive symptoms and the role of the 5-HTTLPR.
Topics: Adult; Alleles; Depression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Longitudina | 2013 |
High plasma monoamine metabolite levels in Cotard's syndrome.
Topics: Catecholamines; Delusions; Depression; Female; Homovanillic Acid; Humans; Methoxyhydroxyphenylglycol | 2014 |
Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Brain; Chromatography, High Pressure Liquid; | 2014 |
Depressive Behavior and Monoamine Contents in Brain Structures of Rats During Chronic Overcrowding.
Topics: Animals; Behavior, Animal; Brain; Depression; Dopamine; Homovanillic Acid; Hypothalamus; Norepinephr | 2015 |
Neuroanatomic pathways associated with monoaminergic dysregulation after stroke.
Topics: Adult; Affective Symptoms; Aged; Aged, 80 and over; Apathy; Basal Ganglia; Biogenic Monoamines; Depr | 2017 |
Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.
Topics: Animals; Anxiety; Behavior; Cytokines; Depression; Dopamine; Homovanillic Acid; Humans; Indoleamine- | 2009 |
Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.
Topics: Adult; Analysis of Variance; Blood-Brain Barrier; Cytokines; Depression; Female; Homovanillic Acid; | 2009 |
Plasma homovanillic acid in adolescents with bulimia nervosa.
Topics: Adolescent; Body Mass Index; Bulimia Nervosa; Chromatography, High Pressure Liquid; Depression; Elec | 2009 |
[Alcoholism and depression: catecholamines and brain-derived neurotrophic factors].
Topics: Adult; Aged; Alcoholism; Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Catec | 2009 |
Co-involvement of psychological and neurological abnormalities in infertility with polycystic ovarian syndrome.
Topics: 3,4-Dihydroxyphenylacetic Acid; Anxiety; Checklist; Depression; Diagnostic Self Evaluation; Dopamine | 2011 |
Plasma levels of metabolites of catecholamine in nicotine-dependent patients treated with varenicline.
Topics: Adult; Benzazepines; Catecholamines; Depression; Female; Homovanillic Acid; Humans; Male; Methoxyhyd | 2012 |
Neurochemical consequence of steroid abuse: stanozolol-induced monoaminergic changes.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Depression; Dopamine; Hippocampus; Homovan | 2012 |
Influence of aging and social isolation on changes in brain monoamine turnover and biosynthesis of rats elicited by novelty stress.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Biogenic Monoamines; Brain; Chromatography, High Pre | 2002 |
Oestrogen-deficient female aromatase knockout (ArKO) mice exhibit depressive-like symptomatology.
Topics: Animals; Anxiety; Aromatase; Behavior, Animal; Biogenic Monoamines; Brain; Brain Chemistry; Depressi | 2004 |
5-Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Depression; Dopamine; Female; Homovanillic Acid; Human | 2004 |
Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients.
Topics: Adult; Case-Control Studies; Depression; Electrochemistry; Female; Homovanillic Acid; Humans; Hydroc | 2006 |
CSF monoamine metabolites and lethality of suicide attempts in depressed patients with alcohol dependence.
Topics: Adult; Alcoholism; Biogenic Monoamines; Depression; Female; Homovanillic Acid; Humans; Hydroxyindole | 2007 |
Psychopathological and nutritional correlates of plasma homovanillic acid in adolescents with anorexia nervosa.
Topics: Adolescent; Anorexia Nervosa; Depression; Female; Follow-Up Studies; Homovanillic Acid; Humans; Male | 2008 |
Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Depression; Dopamine; Female; Hallucinations; Haloperidol; | 2007 |
Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
Topics: Animals; Antidepressive Agents, Second-Generation; Arginine; Behavior, Animal; Body Temperature; Bra | 2007 |
Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Chromatography, High | 2007 |
Cortisol in the CSF of depressed and suicidal patients.
Topics: Adjustment Disorders; Clomipramine; Depression; Female; Homovanillic Acid; Humans; Hydrocortisone; H | 1980 |
Substances related to 5-hydroxytryptamine in plasma and in lumbar and ventricular fluids of psychiatric patients.
Topics: Adult; Affective Symptoms; Cerebral Ventricles; Depression; Fatty Acids, Nonesterified; Female; Homo | 1980 |
[Current biochemical conceptions of mental diseases. II. Role of changes in the biogenic amine system in the pathogenesis of affective disorders].
Topics: 3-Methoxy-4-hydroxyphenylethanol; Affective Disorders, Psychotic; Antidepressive Agents, Tricyclic; | 1980 |
Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls.
Topics: Blood Platelets; Depression; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M | 1981 |
[Metabolism of peripheral catecholamines and indole amines in healthy persons. Clinico-biochemical correlates].
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Carboxylic Acids; Catecholamines; Depression; Female; Glycols | 1981 |
[Changes in the levels of adrenergic and serotoninergic indices in patients with depressive states].
Topics: Adolescent; Adult; Biogenic Amines; Depression; Dihydroxyphenylalanine; Dopamine; Epinephrine; Homov | 1981 |
Psychic disturbances in adult coeliac disease. III. Reduced central monoamine metabolism and signs of depression.
Topics: Adult; Aged; Biogenic Amines; Celiac Disease; Depression; Dopamine; Homovanillic Acid; Humans; Hydro | 1982 |
Amine metabolites and neuroendocrine responses related to depression and suicide.
Topics: Alcoholism; Depression; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydro | 1983 |
Altered serotonin metabolism in depressed patients with parkinson's disease.
Topics: Aged; Depression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyp | 1984 |
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression; | 1984 |
CSF monoamine metabolites in depression and schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Depression; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1980 |
Depletion of mesolimbic dopamine during behavioral despair: partial reversal by chronic imipramine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Depression; Disease Models, Animal; Dopami | 1993 |
Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Topics: Adult; Aged; Antipsychotic Agents; Depression; Dopamine D2 Receptor Antagonists; Dose-Response Relat | 1996 |
Reduced dopamine turnover in the basal ganglia of depressed suicides.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adult; Aged; Antidepressive Agents; Basal Ganglia; Chrom | 1997 |
Differences in whole blood serotonin levels based on a typology of parasuicide.
Topics: Adult; Analysis of Variance; Biomarkers; Case-Control Studies; Depression; Female; Homovanillic Acid | 1998 |
Genetic alteration of the alpha2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cerebral Cortex; Corpus Striatum; Cortico | 1999 |
[The concept of schizoaffective disorder: paraclinical validity of schizoaffective disorder].
Topics: Delirium; Depression; Homovanillic Acid; Humans; Monoamine Oxidase; Psychiatric Status Rating Scales | 1999 |
Severity of depression in abstinent alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate concentrations.
Topics: Adult; Case-Control Studies; Dehydroepiandrosterone; Depression; Ethanol; Female; Homovanillic Acid; | 1999 |
Limbic dopaminergic adaptation to a stressful stimulus in a rat model of depression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Depression; Disease Models, Anim | 2001 |
Opposite genotype-dependent mesocorticolimbic dopamine response to stress.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Depression; Disease Models, Animal; Dopam | 2001 |
Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents, Tricyclic; Depression; Desipramine; | 2001 |
Attenuating effects of the isolated rearing condition on increased brain serotonin and dopamine turnover elicited by novelty stress.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Depression; Dopamine; Exploratory Behavior; Homovani | 2002 |
Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects.
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Depression; Homovanillic Acid; Humans; Hydroxyindole | 1976 |
Prolactin in cerebrospinal fluid and dopamine function in man.
Topics: Brain; Depression; Dopamine; Homovanillic Acid; Humans; Piribedil; Prolactin | 1976 |
Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine.
Topics: Biogenic Amines; Clomipramine; Depression; Depression, Chemical; Dibenzazepines; Homovanillic Acid; | 1977 |
Familial fatal Parkinsonism with alveolar hypoventilation and mental depression.
Topics: Brain; Brain Chemistry; Depression; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Glutamate | 1979 |
Delusional versus non-delusional depression: Neurochemical differences.
Topics: Adult; Delusions; Depression; Drug Resistance; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1978 |
Interactions between central monoaminergic systems: dopamine-serotonin.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Depression; Dopamine; Dyskinesia, Drug-Induced; Female; H | 1979 |
[REM sleep deprivation in normal humans. Changes in anxiety, depression and aggressiveness, and HVA and 5-HIAA levels in the lumbar cerebrospinal fluid].
Topics: Adult; Aggression; Anxiety; Depression; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; P | 1976 |
Biological and behavioral effects of one night's sleep deprivation in depressed patients and normals.
Topics: Adult; Aged; Bipolar Disorder; Body Temperature; Calcium; Circadian Rhythm; Depression; Electroencep | 1979 |
Cerebrospinal fluid cyclic AMP and acid monoamine metabolites following probenecid: studies in psychiatric patients.
Topics: Adolescent; Adult; Aged; Biogenic Amines; Chlorpromazine; Cyclic AMP; Depression; Female; Homovanill | 1979 |
Biochemistry of the affective disorders.
Topics: Affective Symptoms; Bipolar Disorder; Body Temperature; Cholinesterase Inhibitors; Circadian Rhythm; | 1979 |
Manipulation of neurotransmitters by acupuncture (?) (A preliminary communication).
Topics: Acupuncture Therapy; Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Depression; Fema | 1975 |
The Harold E. Himwich Memorial Lecture. Significance of biochemical parameters in the diagnosis, treatment, and prevention of depressive disorders.
Topics: 5-Hydroxytryptophan; Antidepressive Agents, Tricyclic; Autopsy; Bipolar Disorder; Brain Chemistry; C | 1977 |
Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant.
Topics: Adult; Antidepressive Agents; Blood Platelets; Depression; Dystonia; Extrapyramidal Tracts; Female; | 1979 |
Deficient production of tyramine and octopamine in cases of depression.
Topics: Aged; Depression; Female; Homovanillic Acid; Humans; Hydroxy Acids; Male; Mandelic Acids; Middle Age | 1979 |
Pituitary thyrotropin response to thyrotropin-releasing hormone in affective illness: relationship to spinal fluid amine metabolites.
Topics: Age Factors; Bipolar Disorder; Depression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Ac | 1977 |
Naloxone (Narcan) treatment in depression: clinical observations and effects on CSF endorphins and monoamine metabolites.
Topics: Adult; Alcoholism; Biogenic Amines; Depression; Endorphins; Female; Homovanillic Acid; Humans; Hydro | 1977 |
Repertory grid and biochemical characterization of depression: a comparison of case reports.
Topics: 3,4-Dihydroxyphenylacetic Acid; Depression; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1979 |
Lithium: clinical effects and cerebrospinal fluid acid monoamine metabolites.
Topics: Adult; Affective Symptoms; Aged; Biogenic Amines; Bipolar Disorder; Depression; Electroencephalograp | 1977 |
Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders.
Topics: Adult; Aged; Biogenic Amines; Bipolar Disorder; Depression; Female; Homovanillic Acid; Humans; Hydro | 1978 |
Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid.
Topics: Clorgyline; Depression; Dopamine; Homovanillic Acid; Humans; Norepinephrine; Pargyline; Propylamines | 1979 |
Cerebrospinal fluid amine metabolites after combined amitriptyline-triiodothyronine treatment of depressed women.
Topics: Adult; Amitriptyline; Biogenic Amines; Depression; Drug Therapy, Combination; Female; Homovanillic A | 1977 |
Nonstriatal dopaminergic neurons: Section XI. Dopaminergic neurons and mental diseases: Introduction: dopaminergic neurons and mental diseases.
Topics: Apomorphine; Bromocriptine; Catecholamines; Depression; Dopamine; Homovanillic Acid; Humans; Levodop | 1977 |
CSF amine metabolites, clinical symptoms, and body movement in psychiatric patients.
Topics: Adult; Anger; Anxiety; Arousal; Brain; Depression; Female; Homovanillic Acid; Humans; Hydroxyindolea | 1976 |
A dopaminergic mechanism in mania.
Topics: Bipolar Disorder; Depression; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Lithium | 1976 |
Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
Topics: Adult; Aged; Brain Damage, Chronic; Depression; Female; Hallucinations; Haloperidol; Homovanillic Ac | 1976 |
Precursors and metabolites of 5-hydroxytryptamine and dopamine in the ventricular cerebrospinal fluid of psychiatric patients.
Topics: Adult; Aged; Anxiety Disorders; Brain Diseases; Cerebral Ventricles; Depression; Female; Homovanilli | 1976 |
[Repeated arousal during non-REM sleep in normal humans. Changes in anxiety, depression and aggressiveness and HVA and 5-HIAA levels in the lumbar cerebrospinal fluid].
Topics: Adult; Aggression; Anxiety; Depression; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; P | 1976 |
[Total sleep deprivation in normal humans. Changes in anxiety, depression and aggressiveness and HVA and 5-HIAA levels in the lumbar cerebrospinal fluid].
Topics: Adult; Anxiety; Depression; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Phenylacetate | 1976 |
Effect of l-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients.
Topics: 5-Hydroxytryptophan; Adjustment Disorders; Adult; Aged; Blood Platelets; Brain; Depression; Female; | 1975 |
Central monoamine deficiency in depressions: causative of secondary phenomenon?
Topics: 5-Hydroxytryptophan; Clomipramine; Depression; Dopamine; Homovanillic Acid; Humans; Serotonin | 1975 |
Gradients of biogenic amine metabolites in cerebrospinal fluid.
Topics: Alzheimer Disease; Amphetamine; Brain Diseases; Brain Neoplasms; Depression; Homovanillic Acid; Huma | 1975 |
Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders.
Topics: Adjustment Disorders; Bipolar Disorder; Brain; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; D | 1975 |
Central noradrenergic function in man: vanillylmandelic acid in CSF.
Topics: Acute Disease; Affective Symptoms; Bipolar Disorder; Depression; Homovanillic Acid; Humans; Hydroxyi | 1975 |
Biochemical post-mortem findings in depressed patients.
Topics: Aged; Brain Chemistry; Brain Mapping; Circadian Rhythm; Depression; Dopamine; Female; Homovanillic A | 1975 |
Effect of peripheral decarboxylase inhibition on HVA and 5HIAA in cerebrospinal fluid of depressed patients.
Topics: Adult; Aged; Benserazide; Depression; Female; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleac | 1975 |
Cerebrospinal fluid amine metabolites in affective illness and schizophrenia: clinical and pharmacological studies.
Topics: Affective Symptoms; Amines; Depression; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Imipram | 1975 |
Concentration of 5-hydroxyindoleacetic acid, homovanillic acid, and tryptophan in the cerebrospinal fluid of depressed patients before and after ECT.
Topics: Adult; Brain; Depression; Electroconvulsive Therapy; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1976 |
Effects of sleep deprivation on mood and central amine metabolism in depressed patients.
Topics: Adult; Affect; Aged; Brain; Depression; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleac | 1976 |
Neurochemical correlates of major depression in primary dementia.
Topics: Brain; Choline O-Acetyltransferase; Dementia; Depression; Homovanillic Acid; Humans; Hydroxyindoleac | 1990 |
Biochemical correlate of depression in children.
Topics: Adolescent; Age Factors; Analysis of Variance; Catecholamines; Child; Child, Abandoned; Depression; | 1991 |
Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites.
Topics: Adult; Blood Platelets; Depression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Kin | 1987 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanill | 1989 |
Differences in lithium effects in depressed and healthy subjects.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Depression; Dopamine; Homovanillic Acid; Humans; Hydroxyindol | 1985 |
Neurotransmission and the experience of low back pain; no association between CSF monoamine metabolites and pain.
Topics: Adult; Anxiety; Back Pain; Depression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; | 1985 |
Changes on recovery in the concentrations of tryptophan and the biogenic amine metabolites in the cerebrospinal fluid of patients with affective illness.
Topics: Adult; Affective Symptoms; Antipsychotic Agents; Biogenic Amines; Bipolar Disorder; Butyrophenones; | 1973 |
Brain serotonin, affective illness, and antidepressant drugs: cerebrospinal fluid studies with probenecid.
Topics: Affective Symptoms; Amitriptyline; Antidepressive Agents; Brain; Brain Chemistry; Depression; Fenclo | 1974 |
Psychomotor activity, sleep, and biogenic amine metabolites in depression.
Topics: Adult; Biological Transport, Active; Circadian Rhythm; Depression; Electroencephalography; Electromy | 1974 |
CSF monoamine metabolites in alcoholism: a comparative study with depression.
Topics: Adult; Aged; Alcoholism; Depression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Ma | 1974 |
Amphetamine psychosis: behavioral and biochemical aspects.
Topics: Adolescent; Adult; Affect; Alcoholism; Amphetamine; Brain; Cognition Disorders; Delusions; Depressio | 1974 |
Lumbar CSF 5-hydroxyindoleacetic acid and homovanillic acid in affective syndromes.
Topics: Adult; Affective Symptoms; Amitriptyline; Animals; Bipolar Disorder; Brain Chemistry; Cats; Depressi | 1974 |
The daily rhythm of HVA, VMA, (VA) and 5-HIAA in depression-syndrome.
Topics: Benzoates; Chromatography, Thin Layer; Circadian Rhythm; Depression; Homovanillic Acid; Humans; Hydr | 1974 |
[Characteristics of catecholamine metabolism in patients with endogenic depressions in the process of unloading-diet therapy].
Topics: Adult; Depression; Dopamine; Epinephrine; Fasting; Homovanillic Acid; Humans; Male; Norepinephrine; | 1974 |
Toward a biochemical classification of depression.
Topics: Antidepressive Agents; Biogenic Amines; Brain; Brain Stem; Depression; Dopamine; Homovanillic Acid; | 1974 |
Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in parkinsonism.
Topics: Age Factors; Aged; Biogenic Amines; Depression; Dihydroxyphenylalanine; Emotions; Female; Homovanill | 1974 |